TELIX Pharmaceuticals (ASX: TLX) – Telix Releases HY26 Results Presentation
Telix Pharmaceuticals reported first-half 2026 revenue of US$477 million, up 22% on the prior year, and the result moved the company firmly into...
ASX Announcements
Cuscal (ASX: CCL) – Cuscal Files FY26 Results Presentation
Cuscal has reported underlying net profit after tax (NPAT) growth of 20 percent for FY26, reaching A$46.2 million, supported by organic expansion...
TELIX Pharmaceuticals (ASX: TLX) – Telix Announces Half Year 2026 Results
Telix Pharmaceuticals delivered strong H1 2026 results that underscore the company's ability to execute commercially while advancing a late-stage...
Cuscal (ASX: CCL) – Cuscal Reports FY26 Full Year Results
Cuscal Limited reported a 49% increase in statutory net profit after tax to $42.7 million for FY26, though this headline figure reflects a...
IPH (ASX: IPH) – IPH FY26 Results Investor Presentation
IPH increased its full-year dividend by 5.5% to 38.5 cents per share despite reported underlying EBITDA declining 0.6% to $205.9m. This apparent...